Next-generation sequencing technology in cancer
Rattachement africain : in, iq. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Next-generation sequencing (NGS) technology has revolutionized cancer research and treatment by enabling comprehensive analysis of genetic mutations, alterations, and expression profiles. It allows for the identification of cancer-driving mutations, helping in the development of targeted therapies. NGS provides detailed insights into tumor heterogeneity, resistance mechanisms, and clonal evolution. Its high-throughput capacity facilitates large-scale studies, improving our understanding of cancer genomics. By enabling personalized treatment plans based on individual genetic profiles, NGS holds promise for more effective and tailored cancer therapies. Early reviews on cancer genomics often lacked comprehensive coverage of emerging technologies. They missed in-depth analysis of NGS advancements, their impact on cancer research, and clinical applications. The review addresses this gap by reviving a thorough examination of NGS methods, their role in identifying genetic mutations, and their potential in personalized cancer treatment, thus providing essential insights into the evolving landscape of cancer genomics. The article covers the advancements in technology and bioinformatic approaches for NGS data analysis. It delves into NGS applications in research and diagnostics, particularly for solid cancer diagnosis. The review highlights specific cancer types, including hereditary breast cancer, melanoma, prostate cancer, thyroid cancer, lung cancer, and colorectal cancer. It explores NGS contribution in understanding the genetic basis of these cancers and its potential for enhancing personalized diagnosis and treatment strategies. This review rectifies early lacunas by providing a comprehensive and updated examination of NGS technology, addressing gaps in previous analyses and emphasizes bioinformatic approaches for NGS data analysis, crucial for interpreting vast genomic data accurately. The review meets the current need for a thorough understanding of NGS’s role in personalized cancer treatment and research.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Next-generation sequencing technology in cancer
- Date Crossref
- 18/07/2024
- Éditeur
- Lapin Press Publications (LPP)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Vellore Institute of Technology University pays non établi dans la noticeUniversité ou école supérieure
-
Lalit Narayan Mithila University pays non établi dans la noticeUniversité ou école supérieure
-
University of Baghdad pays non établi dans la noticeUniversité ou école supérieure
-
St. John's National Academy of Health Sciences pays non établi dans la noticeÉtablissement de santé
-
School of biosciences and technology UG Scholar pays non établi dans la noticeUniversité ou école supérieure
-
Post Graduate Department of Chemistry M. L. S. M. College pays non établi dans la noticeUniversité ou école supérieure
-
Sahibganj College P. G. Department of Chemistry pays non établi dans la noticeUniversité ou école supérieure
-
Assistant Professor (Cancer Research) Department of Family Medicine St. Johns National Academy of Health Sciences pays non établi dans la noticeInstitution
Vellore Institute of Technology University, Lalit Narayan Mithila University et University of Baghdad, avec 5 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.